Medicine details

ImageDEU IV
NameDEU IV
DosageInjection
Generic NameOmeprazole
Classes Gastrointestinal Agent
Antiulcerants
Proton Pump Inhibitor (PPI)
Diseases Dyspepsia
Gastrointestinal Disease
GERD (Gastroesophageal Reflux Disease)
Heart Burn
Ulcer
CompanyMonicopharma Limited

Drug Package Details

Strength40 mg/vial
Storage Condition
Origin CountryBangladesh
Commercial Pack1
Price per pack80.00
Cost per pack70.40
Package unit1 vial strip
Price per unit80.00
Cost per unit70.40
Discount0
Coupon
Remarks

Omeprazole

Omeprazole is a selective and irreversible proton pump inhibitor. It suppresses stomach acid secretion by specific inhibition of the H+/K+-ATPase system found at the secretory surface of gastric parietal cells.

Omeprazole is indicated for the following conditions-

  • Duodenal Ulcer
  • Gastric Ulcer (adults)
  • Treatment of Gastroesophageal Reflux Disease (GERD) (adults and pediatric patients)
  • Erosive Esophagitis
  • Maintenance of Healing of Erosive Esophagitis (adults and pediatric patients)
  • Pathological Hypersecretory Conditions (Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis)
  • Omeprazole Delayed-Release Capsules should be taken before eating. In the clinical trials, antacids were used concomitantly with Omeprazole.
  • Patients should be informed that the Omeprazole Delayed-Release Capsule should be swallowed whole.

Short-Term Treatment of Active Duodenal Ulcer
The recommended adult oral dose of Omeprazole is 20 mg once daily. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.

  • H. pylori Eradication for the Reduction of the Risk of Duodenal Ulcer Recurrence:
    Triple Therapy (Omeprazole/clarithromycin/amoxicillin): The recommended adult oral regimen is Omeprazole 20 mg plus clarithromycin 500 mg plus amoxicillin 1000 mg each given twice daily for 10 days. In patients with an ulcer present at the time of initiation of therapy, an additional 18 days of Omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief.
  • Dual Therapy (Omeprazole/clarithromycin): The recommended adult oral regimen is Omeprazole 40 mg once daily plus clarithromycin 500 mg three times daily for 14 days. In patients with an ulcer present at the time of initiation of therapy, an additional 14 days of Omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief.

Gastric Ulcer
The recommended adult oral dose is 40 mg once daily for 4-8 weeks.

Gastroesophageal Reflux Disease (GERD)
The recommended adult oral dose for the treatment of patients with symptomatic GERD and no esophageal lesions is 20 mg daily for up to 4 weeks. The recommended adult oral dose for the treatment of patients with erosive esophagitis and accompanying symptoms due to GERD is 20 mg daily for 4 to 8 weeks.

Maintenance of Healing of Erosive Esophagitis: The recommended adult oral dose is 20 mg daily.

Pathological Hypersecretory Conditions
The dosage of Omeprazole in patients with pathological hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Doses up to 120 mg three times daily have been administered. Daily dosages of greater than 80 mg should be administered in divided doses. Some patients with Zollinger-Ellison syndrome have been treated continuously with Omeprazole for more than 5 years.

Pediatric Patients

For the treatment of GERD and maintenance of healing of erosive esophagitis, the recommended daily dose for pediatric patients 1 to 16 years of age is as follows:

  • 5 -10 kg: 5 mg
  • 10-20 kg: 10 mg
  • >20 kg: 20 mg

How to use omeprazole powder:

Commonly reported side effects include-

  • Headache
  • Nausea
  • Abdominal pain
  • Diarrhea
  • Vomiting
  • Flatulence
  • Upper respiratory tract infection (pharyngitis, sinusitis)
  • Dizziness
  • Asthenia
  • Cough

 

  • Concomitant Gastric Malignancy: Symptomatic response to therapy with omeprazole does not preclude the presence of gastric malignancy.
  • Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole.
  • Omeprazole therapy may be associated with an increased risk of Clostridium difficile associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve.
  • Omeprazole therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer).
  • The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as omeprazole, that interfere with CYP2C19 activity.
  • Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy.

 

Contraindication

Omeprazole Delayed-Release Capsules are contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Examples of benzimidazole include-

There is no known contraindications of Omeprazole in terms of food and drinks.

There is no known contraindications of Omeprazole in terms of health conditions.